Aperture Venture Partners
Description
Aperture Venture Partners, established in 2018 and based in New York, is a venture capital firm dedicated to investing in early-stage life science companies. The firm strategically focuses on innovative solutions within the medical device, diagnostics, and digital health sectors. With a clear mandate to support groundbreaking technologies, Aperture aims to back companies that are poised to transform healthcare delivery and patient outcomes.
The firm primarily targets Seed and Series A funding rounds, indicating a preference for companies in their formative stages of development. Aperture Venture Partners typically deploys initial checks ranging from $500,000 to $2,000,000, providing crucial early capital to promising startups. Their investment philosophy emphasizes leveraging the partners' deep industry expertise and operational experience to guide portfolio companies through critical growth phases, from product development to market entry.
Aperture's portfolio reflects its commitment to advancing healthcare innovation, featuring companies that are developing novel medical devices, sophisticated diagnostic tools, and impactful digital health platforms. The firm's hands-on approach extends beyond capital infusion, offering strategic guidance and network access to help founders navigate the complex landscape of the life sciences industry. By concentrating on specific, high-potential segments, Aperture Venture Partners positions itself as a specialized and supportive partner for emerging leaders in healthcare technology.
Investor Profile
Aperture Venture Partners has backed more than 60 startups, with 3 new investments in the last 12 months alone. The firm has led 4 rounds, about 7% of its total and boasts 24 exits across its portfolio.
Investment Focus Highlights
- Concentrates on Series C, Series B, Series Unknown rounds (top funding stages).
- Majority of deals are located in United States, Israel.
- Strong thematic focus on Health Care, Biotechnology, Medical Device.
- Typical check size: $500K – $2M.
Stage Focus
- Series C (32%)
- Series B (20%)
- Series Unknown (13%)
- Series A (13%)
- Series D (12%)
- Series E (5%)
- Series F (2%)
- Private Equity (2%)
- Post Ipo Equity (2%)
Country Focus
- United States (95%)
- Israel (5%)
Industry Focus
- Health Care
- Biotechnology
- Medical Device
- Medical
- Therapeutics
- Pharmaceutical
- Life Science
- Wellness
- Health Diagnostics
- Hospital
Frequently Asked Questions
Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.
'%3e%3cpath fill='%23012169' d='M0 0v30h60V0z'/%3e%3cpath stroke='%23fff' stroke-width='6' d='m0 0 60 30m0-30L0 30'/%3e%3cpath stroke='%23C8102E' stroke-width='4' d='m0 0 60 30m0-30L0 30' clip-path='url(%23b)'/%3e%3cpath stroke='%23fff' stroke-width='10' d='M30 0v30M0 15h60'/%3e%3cpath stroke='%23C8102E' stroke-width='6' d='M30 0v30M0 15h60'/%3e%3c/g%3e%3c/svg%3e)
